Experimental Gel to Improve Female Libido Fails

Identifying a remedy for Female Sexual Dysfunction is still a task that needs to reach its required culmination. All the medicinal attempts to enhance female sexual satisfaction, especially in post menopausal women seems to be getting mixed results. So the so called ‘female Viagra’ is still some distance away.

Attempts such as Intrinsa by Proctor and Gamble, which was created after a lot of research for women with low or depleting levels of testosterone and estrogen failed eventually. This was created for women up to the age of sixty. Female body faces lack of testosterone either because of physical inactivity or due to removal of ovaries which produce these hormones. Intrinsa worked in a manner that allowed testosterone percolating from the skin down to the blood. It was rejected by Medical authorities on the grounds that though it managed to heighten the testosterone levels in females but did not increase the Libido.

In 2009, Flibanaserin, came in asanother drug that tried to claim the status of female Viagra as it displayed increase in libido desire for women in three medical trials successfully but in 2010 the Food and Drugs Association declared its results as “not particularly compelling”. The users of the drug also have reported to have side effects such as dizziness, anxiety, insomnia and nausea. And critics call it just a high intensity anti-depressant. A few other anti depressant drugs which were used by the doctors to treat FSD were also banned due to increased chances of heart strokes.

The latest on the podium was Libi Gel by the pharmaceutical company Bio Santé. It was created for post menopausal women who face loss of drive because of Sexual Dysfunction or Hypoactive sexual desire disorder. It was created as a low testosterone level, daily drug for increasing the Libido, as the name suggests. The drug that entered its third stage of trials this month failed to emerge as a breakthrough. Since no other testosterone drug was given a green signal made it even more pertinent for the organisation to see it get approved. But the FDA still has concerns on the drug.